Nanocarriers Global Market Report 2026

Nanocarriers are nanoscale delivery platforms designed to transport drugs, genes, or other therapeutic agents with precise targeting, delivering them directly to specific cells or tissues in the body. These sophisticated systems enhance the stability and bioavailability of treatments, enable controlled and prolonged release, and reduce side effects by limiting exposure to non-target healthy tissues.

The primary categories of nanocarriers include polymeric nanocarriers, lipid-based nanocarriers, inorganic nanocarriers, and additional types. Polymeric nanocarriers consist of nanoscale systems based on polymers, engineered to transport drugs or therapeutic agents effectively to specific locations within the body. They find use in areas like drug delivery, diagnostics, vaccines, gene therapy, and more, catering to end-users such as pharmaceutical and biotechnology firms, hospitals and clinics, research institutions, and others.

Tariffs are influencing the nanocarriers market by increasing costs of imported nanomaterials, specialized polymers, lipids, laboratory equipment, and precision manufacturing tools required for nanoscale formulation. Pharmaceutical and biotechnology companies in North America and Europe are most affected due to reliance on imported high-purity inputs, while Asia-Pacific faces higher costs for export-oriented nanomaterial production. These tariffs are increasing R&D and production expenses and slowing commercialization timelines. However, they are also encouraging domestic nanomaterial manufacturing, regional research collaboration, and localized scale-up of nanocarrier production.

The nanocarriers market research report is one of a series of new reports from The Business Research Company that provides nanocarriers market statistics, including nanocarriers industry global market size, regional shares, competitors with a nanocarriers market share, detailed nanocarriers market segments, market trends and opportunities, and any further data you may need to thrive in the nanocarriers industry. This nanocarriers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The nanocarriers market size has grown rapidly in recent years. It will grow from $11.61 billion in 2025 to $13.74 billion in 2026 at a compound annual growth rate (CAGR) of 18.4%. The growth in the historic period can be attributed to advancements in nanotechnology research, increasing pharmaceutical R&D investments, growing need for improved drug bioavailability, early adoption of nanoparticle-based therapeutics, expansion of academic and clinical research.

The nanocarriers market size is expected to see rapid growth in the next few years. It will grow to $26.74 billion in 2030 at a compound annual growth rate (CAGR) of 18.1%. The growth in the forecast period can be attributed to increasing demand for personalized therapeutics, rising investments in advanced drug delivery systems, expansion of nanocarrier applications in oncology and gene therapy, growing focus on reducing drug side effects, continued innovation in nanoscale engineering. Major trends in the forecast period include increasing development of targeted drug delivery platforms, growing adoption of lipid and polymeric nanocarriers, rising focus on controlled and sustained release systems, expansion of nanocarriers in gene and vaccine delivery, enhanced integration with precision medicine approaches.

The growing demand for personalized medicines is set to boost the nanocarriers market in the future. Personalized medicine involves customizing medical treatments to match each patient's unique traits, especially through genetic, biomarker, and molecular data. Focus on personalized medicine is increasing because it enables physicians to adapt cancer therapies to a patient's genetic makeup, enhancing outcomes and minimizing avoidable side effects. Nanocarriers support personalized medicine by delivering drugs accurately to targets specific to the patient, regulating release, boosting bioavailability, and enabling customized combination treatments aligned with individual biology. For example, in February 2024, the Personalized Medicine Coalition-a US-based nonprofit-reported that the United States Food and Drug Administration (FDA) approved 16 new personalized therapies for rare diseases in 2023, up significantly from only six in 2022. Thus, the surging demand for personalized medicines is fueling expansion in the nanocarriers market.

Major companies in the nanocarriers market are focusing on advanced formulations, such as lipid nanoparticle technologies, to boost targeted drug delivery and therapeutic effectiveness. These technologies involve nanoscale, lipid-based carriers that transport drugs or genetic therapies to specific cells or tissues in a safe and efficient manner. For example, in July 2023, Cytiva-a US-based biotechnology firm-introduced the NanoAssemblr commercial formulation system, a fully automated, single-use platform for complete clinical and commercial production of lipid nanoparticle (LNP) medicines. Powered by Cytiva's NxGen technology, this system delivers precise, reproducible mixing to maintain uniform quality from research through large-scale cGMP manufacturing. Its single-use fluid path minimizes cross-contamination risks and enables efficient multi-product production within a single facility. Additionally, the platform includes user-friendly software that meets regulatory requirements, automates processes, and supports electronic batch records to simplify the creation of genomic medicines like mRNA vaccines, gene therapies, and cancer vaccines.

In August 2024, VION Biosciences LLC, a US-based life science platform company, acquired Echelon Biosciences Inc., a US-based biotechnology company that manufactures lipid nanoparticles (LNPs)-a crucial nanocarrier for mRNA-based therapies-for an undisclosed amount, aiming to better serve customers developing diverse mRNA and gene-based biotherapeutics by expanding its portfolio, bolstering drug discovery and preclinical capabilities, and entering the drug manufacturing space.

Major companies operating in the nanocarriers market are F. Hoffmann-La Roche Ltd, Pfizer Inc., Sanofi S.A., Novartis AG, Bristol-Myers Squibb Company, Amgen Inc., Evonik Industries AG, Matinas BioPharma Holdings Inc., Luye Pharma Group Ltd., Ascendia Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., Nanobiotix S.A., Polymun Scientific Immunbiologische Forschung GmbH, ReCode Therapeutics Inc., Celsion Corporation, Starpharma Holdings Limited, EnGeneIC Ltd., Acuitas Therapeutics Inc., Altamira Therapeutics Ltd., Nanexa AB

North America was the largest region in the nanocarriers market in 2025. The regions covered in the nanocarriers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the nanocarriers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The nanocarriers market consists of sales of polymeric nanoparticles, nanocrystals, carbon nanotubes, exosomes, and quantum dots. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Nanocarriers Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses nanocarriers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for nanocarriers ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The nanocarriers market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Polymeric Nanocarriers; Lipid-Based Nanocarriers; Inorganic Nanocarriers; Other Types
• 2) By Application: Drug Delivery; Diagnostics; Vaccines; Gene Therapy; Other Applications
• 3) By End-User: Pharmaceutical And Biotechnology Companies; Hospitals And Clinics; Research Institutes; Other End-Users
• Subsegments:
• 1) By Polymeric Nanocarriers: Nanoparticles Of Poly Lactic Acid; Nanoparticles Of Poly Lactic-Co-Glycolic Acid; Nanoparticles Of Chitosan; Nanoparticles Of Gelatin; Nanoparticles Of Polycaprolactone
• 2) By Lipid-Based Nanocarriers: Solid Lipid Nanoparticles; Nanostructured Lipid Carriers; Liposomes; Nanoemulsions; Self-Emulsifying Drug Delivery Systems
• 3) By Inorganic Nanocarriers: Gold Nanoparticles; Silver Nanoparticles; Silica Nanoparticles; Magnetic Nanoparticles; Quantum Dots
• 4) By Other Types: Dendrimers; Protein-Based Nanocarriers; Carbon Nanotubes; Nanocrystals; Exosomes
• Companies Mentioned: F. Hoffmann-La Roche Ltd; Pfizer Inc.; Sanofi S.A.; Novartis AG; Bristol-Myers Squibb Company; Amgen Inc.; Evonik Industries AG; Matinas BioPharma Holdings Inc.; Luye Pharma Group Ltd.; Ascendia Pharmaceuticals Inc.; Arcturus Therapeutics Holdings Inc.; Nanobiotix S.A.; Polymun Scientific Immunbiologische Forschung GmbH; ReCode Therapeutics Inc.; Celsion Corporation; Starpharma Holdings Limited; EnGeneIC Ltd.; Acuitas Therapeutics Inc.; Altamira Therapeutics Ltd.; Nanexa AB
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.